Feature Image

AXIM® Biotechnologies Begins Year with Positive Study Results for CBD Chewing Gum

AXIM® Biotech starts 2017 by announcing exciting results from the company’s PK/PD study for CanChew® Plus CBD Chewing Gum.

2016 was a significant year for AXIM® Biotechnologies. AXIM’s stock soared, gaining over 2000 percent year over year, and the company secured the funding necessary to pursue a number of clinical trials and studies in their development of cannabinoid-based treatments for indications like multiple sclerosis, psoriasis and eczema, and irritable bowel syndrome (IBS).

AXIM® Biotechnologies also moved last year to secure the rights to their proprietary extraction method, which allows them to isolate high purity cannabinoids, and extended their patent on delayed-release CBD chewing gum to include all cannabinoids.

Fox Business named the company to its list of Top 5 Biotech Stocks of 2016, punctuating what was an essential year for AXIM®. 

AXIM® Biotechnologies announced in November of 2016 that it was undertaking pharmacokinetic/pharmacodynamics (PK/PD) studies with its CanChew Plus® Gum, the first CBD hemp oil chewing gum, to ascertain the potential for a reduction of irritable bowel syndrome (IBS) symptoms in patients. The results of those studies have been released and are overwhelmingly positive.

In discussing the recent news, Medical Marijuana, Inc. CEO Dr. Stuart Titus said, “It is the goal of AXIM® and our entire family of companies to help people suffering from various gastrointestinal disorders with no effective remedies such as IBS. Positive outcomes from these type of studies can help in the immediate need to enter trials for inflammatory bowel disease (IBD) and Crohn’s disease.”

Wageningen University in the Netherlands was the location of the PK/PD studies. The single dose study was performed using 10 mg of CBD and 30 mg of CBD to determine the concentration of CBD present in the blood after chewing one CanChew Plus® Gum for thirty minutes.

These early stage studies are meant to determine the administered dose when the company moves on to Phase II trials. The results of the studies show promising bioavailability in the 30 mg dosage. This data will be used to determine the optimal formulation for the company’s IBS patient trial.

“These results show that excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an easy-to-use solution,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “We believe that we can match or improve the bioavailability profile for CBD compared to other delivery systems such as smoking or oral intake. We look forward to entering clinical trials and making available our cannabis-based medicinal solutions to patients suffering from IBS and other gastrointestinal disorders as soon as possible.”

AXIM® Biotechnologies revealed in December that the company had received approval from the Medical Ethical Committee (METC) of Wageningen University to begin their human trials for CanChew® Plus CBD Gum for the treatment of the symptoms of IBS. The PK/PD studies were a critical step towards completing the studies necessary to file a new drug application for the company’s patented delayed release chewing gum.

In November, the company released their new drug pipeline, revealing their clinical trial schedule for over a dozen novel treatments. Learn more about AXIM® Biotechnologies and portfolio of investment companies on our news feed.

  • January 4, 2017
  • Jeffrey Stamberger